

**Supplementary table s2.** Complete list of the 115 different miRNAs found differentially expressed in the studies included in this scoping review.

**Table 1.** MiRNAs upregulated and downregulated from the included studies in the scoping review.

miRNAs	Cells		Urine/Plasma		Animals		Kidney tissue		Human Urine/ Plasma		Total number of studies where the miRNA was cited
	Upregulated	Downregulated	Upregulated	Downregulated	Upregulated	Downregulated	Upregulated	Downregulated	Upregulated	Downregulated	
<b>miR-34a</b>	Suter-Dick et al., 2018 [20]; Bhatt et al./2010 [35]; Lee at al./2014 [36]		Pavkovic et al., 2014 [25]; Wolenski et al./2017 [28]				Pavkovic et al., 2014 [25]; Wolenski et al./2017 [28]; El Magdoub et al., 2020 [31]; Bhatt et al./2010 [35]; Lee at al./2014 [36]				6
<b>miR-21</b>	Suter-Dick et al., 2018 [20]	Zhang et al., 2015 [18]; Pavkovic et al., 2016 [46]	Pavkovic et al., 2014 [25]; Okamoto et al./2021 [34]				Pavkovic et al., 2014 [25]		Pavkovic et al., 2016 [46]		5
<b>let-7g-5p</b>			Kanki et al., 2014 [24]; Wolenski et al., 2017 [28]	Kagawa et al., 2019 [30]	Lee at al./2014 [36]						4
<b>miR-26a-5p</b>		Yang et al., 2019 [42]	Okamoto et al./2021 [34]	Kagawa et al., 2019 [30]				Lee at al./2014 [36]; Yang et al., 2019 [42]			4
<b>miR-192-5p</b>	Suter-Dick et al./2018 [20]		Kanki et al., 2014 [24]; Pavkovic et al., 2014 [25]	Kagawa et al., 2019 [30]				Pavkovic et al., 2014 [25]			4
<b>miR-30a-5p</b>		Du et al., 2017 [37]	Kanki et al., 2014 [24]	Kagawa et al., 2019 [30]				Du et al., 2017 [37]			3
<b>miR-15b-5p</b>			Pavkovic et al., 2014 [25];					Pavkovic et al., 2014 [25]			2

		Glineur et al., 2018 [29]		
<b>miR-20b-5p</b>		Kanki et al., 2014 [24]; Pavkovic et al., 2014 [25]	Pavkovic et al., 2014 [25]	2
<b>miR-25-3p</b>		Kanki et al., 2014 [24]	Kagawa et al., 2019 [30]	2
<b>miR-26b-3p</b>		Kanki et al., 2014 [24]		1
<b>miR-26b-5p</b>		Wolenski et al., 2017 [28]	El Magdoub et al., 2020 [31]	2
<b>miR-30e</b>	Du et al., 2017 [37]		Lee at al./2014 [36]; Du et al., 2017 [37]	2
<b>miR-34c-5p</b>		Wolenski et al., 2017 [28]; Glineur et al., 2018 [29]		2
<b>miR-122-5p</b>	Lee at al./2014 [36]		Kagawa et al., 2019 [30]	2
<b>miR-130b-3p</b>		Kanki et al., 2014 [24]; Wolenski et al., 2017 [28]		2
<b>miR-140-3p</b>		Kanki et al., 2014 [24]	Kagawa et al., 2019 [30]	2
<b>miR-140-5p</b>		Wolenski et al., 2017 [28]		1
<b>miR-146a</b>		Cho et al.,2017 [26]	Pavkovic et al., 2014 [25]	2
<b>miR-181a</b>	Zhu et al., 2012 [17]		Huang et al.,2020 [32]	2
<b>miR-182-5p</b>	Li et al., 2021 [43]	Glineur et al., 2018 [29]; Li et al., 2021 [43]		2

miR-183-5p		Kanki et al., 2014 [24]; Glineur et al., 2018 [29]		2
miR-191a-5p		Kanki et al., 2014 [24]	Kagawa et al., 2019 [30]	2
miR-193		Pavkovic et al., 2014 [25]		Pavkovic et al., 2014 [25]; Lee at al./2014 [36]
miR-210-3p		Pavkovic et al., 2014 [25]; Glineur et al., 2018 [29]		Pavkovic et al., 2014 [25]
miR-320-3p		Kanki et al., 2014 [24]; Harrill et al., 2017 [27]		2
miR-423-3p	Pavkovic et al., 2016 [46]	Glineur et al., 2018 [29]		Pavkovic et al., 2016 [46]
miR-500a-3p	Jiang et al.,2019 [21]; Zhang et al.,2020 [23]			2
let-7a-1-3p		Kanki et al., 2014 [24]		1
let-7b				El Magdoub et al., 2020 [31]
let-7c-5p			Kagawa et al., 2019 [30]	1
let-7f-5p			Kagawa et al., 2019 [30]	1
let-7i-5p			Kagawa et al., 2019 [30]	1
miR-7a-1-3p		Kanki et al., 2014 [24]		1
miR-9-3p	Wu et al.,2019 [22]			1

<b>miR-10a</b>		Okamoto et al./2021 [34]		1
<b>miR-10b</b>			Lee et al./2014 [36]	1
<b>miR-15</b>		Pavkovic et al., 2014 [25]		1
<b>miR-16</b>		Pavkovic et al., 2014 [25]	Pavkovic et al., 2014 [25]	1
<b>miR-17-5p</b>		Kanki et al., 2014 [24]		1
<b>miR-20a</b>		Pavkovic et al., 2014 [25]	Pavkovic et al., 2014 [25]	1
<b>miR-23a-3p</b>			Kagawa et al., 2019 [30]	1
<b>miR-23b-5p</b>	Wu et al.,2019 [22]			1
<b>miR-27b-5p</b>	Wu et al.,2019 [22]			1
<b>miR-29</b>	Zhang et al., 2015 [18]			1
<b>miR-29a</b>	Suter-Dick et al.,2018 [20]			1
<b>miR-30b</b>	Du et al., 2017 [37]		Du et al., 2017 [37]	1
<b>miR-30c</b>	Du et al., 2017 [37]		Du et al., 2017 [37]	1
<b>miR-30d</b>	Du et al., 2017 [37]		Du et al., 2017 [37]	1
<b>miR-31-3p</b>			Hao et al., 2017 [38]	1
<b>miR-31-5p</b>			Wu et al., 2020 [33]	1
<b>miR-93-5p</b>		Kanki et al., 2014 [24]		1
<b>miR-128</b>		Wolenski et al., 2017 [28]		1

<b>miR-130a</b>		Harrill et al., 2017 [27]		1
<b>miR-138</b>		Harrill et al., 2017 [27]		1
<b>miR-140-5p</b>	Liao et al., 2017 [39]		Liao et al., 2017 [39]	1
<b>miR-141</b>			Pavkovic et al., 2014 [25]	1
<b>miR-143-3p</b>		Kagawa et al., 2019 [30]		1
<b>miR-146b-5p</b>		Kagawa et al., 2019 [30]		1
<b>miR-148a-3p</b>		Kagawa et al., 2019 [30]		1
<b>miR-151-3p</b>		Harrill et al., 2017 [27]		1
<b>miR-152</b>		Harrill et al., 2017 [27]		1
<b>miR-155-5p</b>		Glineur et al., 2018 [29]		1
<b>miR-184</b>			Pavkovic et al., 2014 [25]	1
<b>miR-185</b>		Pavkovic et al., 2014 [25]	Pavkovic et al., 2014 [25]	1
<b>miR-186</b>	Xiong et al., 2021 [44]	Xiong et al., 2021 [44]	Xiong et al., 2021 [44]	1
<b>miR-193-5p</b>		Kanki et al., 2014 [24]		1
<b>miR-193a-3p</b>		Glineur et al., 2018 [29]		1
<b>miR-194-5p</b>	Jiang et al., 2019 [21]			1
<b>miR-196c</b>			Pavkovic et al., 2014 [25]	1
<b>miR-199a-3p</b>	Yang et al., 2019 [41]		Yang et al., 2019 [41]	1

<b>miR-200b</b>	Pavkovic et al., 2014 [25]	Pavkovic et al., 2014 [25]	1
<b>miR-200c</b>	Pavkovic et al., 2016 [46]	Pavkovic et al., 2016 [46]	1
<b>miR-205</b>	Zhang et al., 2015 [18]		1
<b>miR-212</b>		Hao et al., 2017 [38]	1
<b>miR-215</b>		Kagawa et al., 2019 [30]	1
<b>miR-218</b>	Harrill et al., 2017 [27]		1
<b>miR-218a-5p</b>	Kanki et al., 2014 [24]		1
<b>miR-221</b>	Harrill et al., 2017 [27]		1
<b>miR-223</b>		Pavkovic et al., 2014 [25]	1
<b>miR-297</b>	Wu et al.,2019 [22]		1
<b>miR-327</b>		Pavkovic et al., 2014 [25]	1
<b>miR-328</b>	Harrill et al., 2017 [27]		1
<b>miR-328a-3p</b>	Kanki et al., 2014 [24]		1
<b>miR-335</b>	Kanki et al., 2014 [24]		1
<b>miR-339-3p</b>	Pavkovic et al., 2014 [25]		1
<b>miR-340-5p</b>	Kanki et al., 2014 [24]		1
<b>miR-371b-5p</b>	Wu et al.,2019 [22]		1
<b>miR-375</b>	Hao et al., 2017 [38]	Hao et al., 2017 [38]	1

<b>miR-378a</b>	Wolenski et al., 2017 [28]	1
<b>miR-378a-3p</b>	Kagawa et al., 2019 [30]	1
<b>miR-378a-5p</b>	Kanki et al., 2014 [24]	1
<b>miR-449</b>	Qin et al.,2016 [19]	1
<b>miR-486</b>	Kagawa et al., 2019 [30]	1
<b>miR-503</b>	Hao et al., 2017 [38]	1
<b>miR-532-3p</b>	Kanki et al., 2014 [24]	1
<b>miR-547</b>	Hao et al., 2017 [38]	1
<b>miR-577</b>	Jiang et al.,2019 [21]	1
<b>miR-680</b>	Harrill et al., 2017 [27]	1
<b>miR-685</b>	Harrill et al., 2017 [27]	1
<b>miR-709</b>	Guo et al., 2018 [40]	1
<b>miR-743a</b>	Hao et al., 2017 [38]	1
<b>miR-744-5p</b>	Kanki et al., 2014 [24]	1
<b>miR-1236-5p</b>	Wu et al.,2019 [22]	1
<b>miR-1839</b>	Wolenski et al., 2017 [28]	1
<b>miR-1839-5p</b>	Kanki et al., 2014 [24]	1
<b>miR-3135b</b>	Wu et al.,2019 [22]	1

<b>miR-3168</b>		Quintanilha et al., 2021 [45]	1
<b>miR-3605-5p</b>	Wu et al.,2019 [22]		1
<b>miR-4299</b>	Wu et al.,2019 [22]		1
<b>miR-4440</b>	Wu et al.,2019 [22]		1
<b>miR-4485</b>	Wu et al.,2019 [22]		1
<b>miR-4718</b>		Quintanilha et al., 2021 [45]	1
<b>miR-4793-3p</b>	Wu et al.,2019 [22]		1
<b>miR-6125</b>		Quintanilha et al., 2021 [45]	1
<b>miR-6841-5p</b>	Wu et al.,2019 [22]		1



---

## References

1. Jelinek, M.J.; Lee, S.M.; Wyche Okpareke, A.; Wing, C.; Koyner, J.L.; Murray, P.T.; Stadler, W.M.; O' Donnell, P.H. Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. *Clin. Transl. Sci.* **2018**, *11*, 420–427, doi:10.1111/cts.12547.
  2. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. *Kidney Int.* **2008**, *73*, 994–1007, doi:10.1038/sj.ki.5002786.
  3. Waikar, S.S.; Betensky, R.A.; Emerson, S.C.; Bonventre, J. V. Imperfect gold standards for kidney injury biomarker evaluation. *J. Am. Soc. Nephrol.* **2012**, *23*, 13–21, doi:10.1681/ASN.2010111124.
  4. Van Meer, L.; Moerland, M.; Cohen, A.F.; Burggraaf, J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. *Br. J. Clin. Pharmacol.* **2014**, *77*, 947–957, doi:10.1111/bcp.12282.
  5. Waikar, S.S.; Sabbiseti, V.S.; Bonventre, J. V. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. *Kidney Int.* **2010**, *78*, 486–494, doi:10.1038/ki.2010.165.
  6. Saliminejad, K.; Khorram Khorshid, H.R.; Soleymani Fard, S.; Ghaffari, S.H. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. *J. Cell. Physiol.* **2019**, *234*, 5451–5465, doi:10.1002/jcp.27486.
  7. Krol, J.; Loedige, I.; Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. *Nat. Rev. Genet.* **2010**, *11*, 597–610, doi:10.1038/nrg2843.
  8. Zhang, W.; Duan, N.; Zhang, Q.; Song, T.; Li, Z.; Zhang, C.; Chen, X.; Wang, K. DNA methylation mediated down-regulation of miR-370 regulates cell growth through activation of the Wnt/ $\beta$ -catenin signaling pathway in human osteosarcoma cells. *Int. J. Biol. Sci.* **2017**, *13*, 561–573, doi:10.7150/ijbs.19032.
  9. Ambros, V. MicroRNAs and Developmental Timing. *Curr Opin Genet Dev* **2011**, *21*, 511–517, doi:10.1016/j.gde.2011.04.003.MicroRNAs.
  10. Small, E.M.; Olson, E.N. Pervasive roles of microRNAs in cardiovascular biology. *Nature* **2011**, *469*, 336–342, doi:10.1038/nature09783.
  11. Chong, M.M.W.; Zhang, G.; Cheloufi, S.; Neubert, T.A.; Hannon, G.J.; Littman, D.R. Canonical and alternate functions of the microRNA biogenesis machinery. *Genes Dev.* **2010**, *24*, 1951–1960, doi:10.1101/gad.1953310.
  12. Li, Y.F.; Jing, Y.; Hao, J.; Frankfort, N.C.; Zhou, X.; Shen, B.; Liu, X.; Wang, L.; Li, R. MicroRNA-21 in the pathogenesis of acute kidney injury. *Protein Cell* **2013**, *4*, 813–819, doi:10.1007/s13238-013-3085-y.
  13. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. *Clin. Chem.* **2010**, *56*, 1733–1741, doi:10.1373/clinchem.2010.147405.
  14. Koturbash, I.; Tolleson, W.H.; Guo, L.; Yu, D.; Chen, S.; Hong, H.; Mattes, W.; Ning, B. MicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. *Biomark. Med.* **2015**, *9*, 1153–1176, doi:10.2217/bmm.15.89.
-

15. Roderburg, C.; Luedde, T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. *J. Hepatol.* **2014**, *61*, 1434–1437, doi:10.1016/j.jhep.2014.07.017.
16. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat. Rev. Drug Discov.* **2017**, *16*, 203–221, doi:10.1038/nrd.2016.246.
17. Zhu, H.Y.; Liu, M.Y.; Hong, Q.; Zhang, D.; Geng, W.J.; Xie, Y.S.; Chen, X.M. Role of microRNA-181a in the apoptosis of tubular epithelial cell induced by cisplatin. *Chin. Med. J. (Engl.)*. **2012**, *125*, 523–526, doi:10.3760/cma.j.issn.0366-6999.2012.03.022.
18. Zhang, H.; Zhang, X.; Yuan, X.; Wang, L.; Xiao, Y. MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4. *Iran. J. Basic Med. Sci.* **2015**, *18*, 1020–1026, doi:10.22038/ijbms.2015.5467.
19. Qin, W.; Xie, W.; Yang, X.; Xia, N.; Yang, K. Inhibiting microrna-449 attenuates cisplatin-induced injury in nrk-52e cells possibly via regulating the sirt1/p53/bax pathway. *Med. Sci. Monit.* **2016**, *22*, 818–823, doi:10.12659/MSM.897187.
20. Suter-Dick, L.; Mauch, L.; Ramp, D.; Caj, M.; Vormann, M.K.; Hutter, S.; Lanz, H.L.; Vriend, J.; Masereeuw, R.; Wilmer, M.J. Combining Extracellular miRNA Determination with Microfluidic 3D Cell Cultures for the Assessment of Nephrotoxicity: a Proof of Concept Study. *AAPS J.* **2018**, *20*, 1–9, doi:10.1208/s12248-018-0245-2.
21. Jiang, L.; Liu, X.Q.; Ma, Q.; Yang, Q.; Gao, L.; Li, H. Di; Wang, J.N.; Wei, B.; Wen, J.; Li, J.; et al. hsa-miR-500a-3P alleviates kidney injury by targeting MLKL-mediated necroptosis in renal epithelial cells. *FASEB J.* **2019**, *33*, 3523–3535, doi:10.1096/fj.201801711R.
22. Wu, J.; Li, D. dan; Li, J. yao; Yin, Y. cong; Li, P. chang; Qiu, L.; Chen, L. meng Identification of microRNA-mRNA networks involved in cisplatin-induced renal tubular epithelial cells injury. *Eur. J. Pharmacol.* **2019**, *851*, 1–12, doi:10.1016/j.ejphar.2019.02.015.
23. Zhang, S.; Sun, H.; Kong, W.; Zhang, B. Functional role of microRNA-500a-3P-loaded liposomes in the treatment of cisplatininduced AKI. *IET Nanobiotechnology* **2020**, *14*, 465–469, doi:10.1049/iet-nbt.2019.0247.
24. Kanki, M.; Moriguchi, A.; Sasaki, D.; Mitori, H.; Yamada, A.; Unami, A.; Miyamae, Y. Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats. *Toxicology* **2014**, *324*, 158–168, doi:10.1016/j.tox.2014.05.004.
25. Pavkovic, M.; Riefke, B.; Ellinger-Ziegelbauer, H. Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury. *Toxicology* **2014**, *324*, 147–157, doi:10.1016/j.tox.2014.05.005.
26. Cho, Y.E.; Kim, S.H.; Lee, B.H.; Baek, M.C. Circulating plasma and exosomal microRNAs as indicators of drug-induced organ injury in rodent models. *Biomol. Ther.* **2017**, *25*, 367–373, doi:10.4062/biomolther.2016.174.
27. Harrill, A.H.; Lin, H.; Tobacyk, J.; Seely, J.C. Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury. *Exp. Biol. Med.* **2017**, *243*, 1–11, doi:10.1177/1535370217740854.
28. Wolenski, F.S.; Shah, P.; Sano, T.; Shinozawa, T.; Bernard, H.; Gallacher, M.J.; Wyllie, S.D.; Varrone, G.; Cicia,

L.A.; Carsillo, M.E.; et al. Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage. *J. Appl. Toxicol.* **2017**, *37*, 278–286, doi:10.1002/jat.3358.

29. Glineur, S.F.; Hanon, E.; Dremier, S.; Snelling, S.; Berteau, C.; De Ron, P.; Nogueira da Costa, A. Assessment of a Urinary Kidney MicroRNA Panel as Potential Nephron Segment-Specific Biomarkers of Subacute Renal Toxicity in Preclinical Rat Models. *Toxicol. Sci.* **2018**, *166*, 409–419, doi:10.1093/toxsci/kfy213.
30. Kagawa, T.; Zárybnický, T.; Omi, T.; Shirai, Y.; Toyokuni, S.; Oda, S.; Yokoi, T. A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. *Toxicology* **2019**, *415*, 26–36, doi:10.1016/j.tox.2019.01.011.
31. El Magdoub, H.M.; Schaalán, M.F.; Rahmo, R.M.; Farag, D.B.; Khedr, L.H. Implications of miRNAs on TGF- $\beta$ /TAK1/mTOR pathway in mediating the renoprotective effects of pentoxifylline against cisplatin-induced nephrotoxicity in rats. *Toxicol. Appl. Pharmacol.* **2020**, *404*, 115184, doi:10.1016/j.taap.2020.115184.
32. Huang, S.J.; Huang, J.; Yan, Y.B.; Qiu, J.; Tan, R.Q.; Liu, Y.; Tian, Q.; Guan, L.; Niu, S.S.; Zhang, Y.; et al. The renoprotective effect of curcumin against cisplatin-induced acute kidney injury in mice: involvement of miR-181a/PTEN axis. *Ren. Fail.* **2020**, *42*, 350–357, doi:10.1080/0886022X.2020.1751658.
33. Wu, Z.; Li, C.; Li, Q.; Li, J.; Lu, X. Puerarin alleviates cisplatin-induced acute renal damage and upregulates microRNA-31-related signaling. *Exp. Ther. Med.* **2020**, *20*, 3122–3129, doi:10.3892/etm.2020.9081.
34. Okamoto, M.; Ichii, O.; Mie, K.; Nishida, H.; Akiyoshi, H. Altered clinicopathology and renal pathology in dogs treated with a clinical dose of cisplatin. *Jpn. J. Vet. Res.* **2021**, *69*, 109–124, doi:10.14943/jjvr.69.2.109.
35. Bhatt, K.; Zhou, L.; Mi, Q.S.; Huang, S.; She, J.X.; Dong, Z. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. *Mol. Med.* **2010**, *16*, 409–416, doi:10.2119/molmed.2010.00002.
36. Lee, C.G.; Kim, J.G.; Kim, H.J.; Kwon, H.K.; Cho, I.J.; Choi, D.W.; Lee, W.H.; Kim, W.D.; Hwang, S.J.; Choi, S.; et al. Discovery of an integrative network of microRNAs and transcriptomics changes for acute kidney injury. *Kidney Int.* **2014**, *86*, 943–953, doi:10.1038/ki.2014.117.
37. Du, B.; Dai, X.M.; Li, S.; Qi, G.L.; Cao, G.X.; Zhong, Y.; Yin, P. di; Yang, X.S. MiR-30c regulates cisplatin-induced apoptosis of renal tubular epithelial cells by targeting Bnip3L and Hspa5. *Cell Death Dis.* **2017**, *8*, 1–13, doi:10.1038/cddis.2017.377.
38. Hao, J.; Lou, Q.; Wei, Q.; Mei, S.; Li, L.; Wu, G.; Mi, Q.S.; Mei, C.; Dong, Z. MicroRNA-375 is induced in cisplatin nephrotoxicity to repress hepatocyte nuclear factor 1- $\beta$ . *J. Biol. Chem.* **2017**, *292*, 4571–4582, doi:10.1074/jbc.M116.754929.
39. Liao, W.; Fu, Z.; Zou, Y.; Wen, D.; Ma, H.; Zhou, F.; Chen, Y.; Zhang, M.; Zhang, W. MicroRNA-140-5p attenuated oxidative stress in Cisplatin induced acute kidney injury by activating Nrf2/ARE pathway through a Keap1-independent mechanism. *Exp. Cell Res.* **2017**, *360*, 292–302, doi:10.1016/j.yexcr.2017.09.019.
40. Guo, Y.; Ni, J.; Chen, S.; Bai, M.; Lin, J.; Ding, G.; Zhang, Y.; Sun, P.; Jia, Z.; Huang, S.; et al. MicroRNA-709 Mediates Acute Tubular Injury through Effects on Mitochondrial Function. *J. Am. Soc. Nephrol.* **2018**, *29*, 449–461,

doi:10.1681/ASN.2017040381.

41. Yang, A.; Liu, F.; Guan, B.; Luo, Z.; Lin, J.; Fang, W.; Liu, L.; Zuo, W. p53 induces miR-199a-3p to suppress mechanistic target of rapamycin activation in cisplatin-induced acute kidney injury. *J. Cell. Biochem.* **2019**, *120*, 17625–17634, doi:10.1002/jcb.29030.
42. Yang, Y.; Li, Z.L.; Wang, F.M.; Tang, R.N.; Tu, Y.; Liu, H. MicroRNA26a inhibits cisplatin-induced renal tubular epithelial cells apoptosis through suppressing the expression of transient receptor potential channel 6 mediated dynamin-related protein 1. *Cell Biochem. Funct.* **2019**, *38*, 384–391, doi:10.1002/cbf.3474.
43. Li, J.; Fan, X.; Wang, Q.; Gong, Y.; Guo, L. Long noncoding RNA PRNCR1 reduces renal epithelial cell apoptosis in cisplatin-induced AKI by regulating miR-182-5p/EZH1. *Kidney Blood Press. Res.* **2021**, *46*, 162–172, doi:10.1159/000510157.
44. Xiong, X.; Tang, B.; Ji, T.; Li, X.; Bai, S. Ameliorative effects of miR-186 on cisplatin-Triggered acute kidney injury via targeting ZEB1. *Am. J. Transl. Res.* **2021**, *13*, 4296–4308.
45. Quintanilha, J.C.F.; Cursino, M.A.; Borges, J.B.; Torso, N.G.; Bastos, L.B.; Oliveira, J.M.; Cobaxo, T.S.; Pincinato, E.C.; Hirata, M.H.; Geraldo, M. V; et al. MiR-3168, miR-6125, and miR-4718 as potential predictors of cisplatin-induced nephrotoxicity in patients with head and neck cancer. *BMC Cancer* **2021**, *21*, 1–10.
46. Pavkovic, M.; Robinson-Cohen, C.; Chua, A.S.; Nicoara, O.; Cárdenas-González, M.; Bijol, V.; Ramachandran, K.; Hampson, L.; Pirmohamed, M.; Antoine, D.J.; et al. Detection of drug-induced acute kidney injury in humans using urinary KIM-1, miR-21, -200c, and -423. *Toxicol. Sci.* **2016**, *152*, 205–213, doi:10.1093/toxsci/kfw077.
47. Mehta, R.L.; Kellum, J.A.; Shah, S. V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A.; Bagga, A.; Bakkaloglu, A.; Bonventre, J. V.; et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. *Crit. Care* **2007**, *11*, 1–8, doi:10.1186/cc5713.
48. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.; Pogossova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 5003–5008, doi:10.1073/pnas.1019055108.
49. Cortez, M.A.; Calin, G.A. MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. *Expert Opin. Biol. Ther.* **2009**, *9*, 703–711, doi:10.1517/14712590902932889.
50. Melkonyan, H.S.; Feaver, W.J.; Meyer, E.; Scheinker, V.; Shekhtman, E.M.; Xin, Z.; Umansky, S.R. Transrenal nucleic acids: From proof of principle to clinical tests. *Ann. N. Y. Acad. Sci.* **2008**, *1137*, 73–81, doi:10.1196/annals.1448.015.
51. Hermeking, H. The miR-34 family in cancer and apoptosis. *Cell Death Differ.* **2010**, *17*, 193–199, doi:10.1038/cdd.2009.56.
52. Chang, T.C.; Wentzel, E.A.; Kent, O.A.; Ramachandran, K.; Mullendore, M.; Lee, K.H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J.; et al. Transactivation of miR-34a by p53 Broadly Influences Gene Expression

and Promotes Apoptosis. *Mol. Cell* **2007**, *26*, 745–752, doi:10.1016/j.molcel.2007.05.010.

53. Manohar, S.; Leung, N. Cisplatin nephrotoxicity: a review of the literature. *J. Nephrol.* **2018**, *31*, 15–25, doi:10.1007/s40620-017-0392-z.
54. Ong, A.L.C.; Ramasamy, T.S. Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. *Ageing Res. Rev.* **2018**, *43*, 64–80, doi:10.1016/J.ARR.2018.02.004.
55. Zhu, S.; Pabla, N.; Tang, C.; He, L.; Dong, Z. DNA damage response in cisplatin-induced nephrotoxicity. *Arch. Toxicol.* **2015**, *89*, 2197–2205, doi:10.1007/s00204-015-1633-3.
56. Chung, A.C.K.; Yu, X.; Lan, H.Y. MicroRNA and nephropathy: Emerging concepts. *Int. J. Nephrol. Renovasc. Dis.* **2013**, *6*, 169–179, doi:10.2147/IJNRD.S37885.
57. Endale, M.; Kim, T.H.; Kwak, Y.S.; Kim, N.M.; Kim, S.H.; Cho, J.Y.; Yun, B.S.; Rhee, M.H. Torilin Inhibits Inflammation by Limiting TAK1-Mediated MAP Kinase and NF- $\kappa$ B Activation. *Mediators Inflamm.* **2017**, *2017*, 1–13, doi:10.1155/2017/7250968.
58. Saal, S.; Harvey, S.J. MicroRNAs and the kidney: coming of age. *Curr. Opin. Nephrol. Hypertens.* **2009**, *18*, 317–323, doi:10.1097/MNH.0b013e32832c9da2.
59. Ma, L.; Qu, L. The function of MicroRNAs in renal development and pathophysiology. *J. Genet. Genomics* **2013**, *40*, 143–152, doi:10.1016/j.jgg.2013.03.002.
60. Du, J.; Cao, X.; Zou, L.; Chen, Y.; Guo, J.; Chen, Z.; Hu, S.; Zheng, Z. MicroRNA-21 and Risk of Severe Acute Kidney Injury and Poor Outcomes after Adult Cardiac Surgery. *PLoS One* **2013**, *8*, 1–8, doi:10.1371/journal.pone.0063390.
61. Zununi Vahed, S.; Omid, Y.; Ardalan, M.; Samadi, N. Dysregulation of urinary miR-21 and miR-200b associated with interstitial fibrosis and tubular atrophy (IFTA) in renal transplant recipients. *Clin. Biochem.* **2017**, *50*, 32–39, doi:10.1016/j.clinbiochem.2016.08.007.
62. Zhong, X.; Chung, A.C.K.; Chen, H.Y.; Dong, Y.; Meng, X.M.; Li, R.; Yang, W.; Hou, F.F.; Lan, H.Y. MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. *Diabetologia* **2013**, *56*, 663–674, doi:10.1007/s00125-012-2804-x.
63. Thum, T.; Catalucci, D.; Bauersachs, J. MicroRNAs: novel regulators in cardiac development and disease. *Cardiovasc. Res.* **2008**, *79*, 562–570, doi:10.1093/cvr/cvn137.
64. Godwin, J.G.; Ge, X.; Stephan, K.; Jurisch, A.; Tullius, S.G.; Iacomini, J. Identification of a microRNA signature of renal ischemia reperfusion injury. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 14339–14344, doi:10.1073/pnas.0912701107.
65. Liu, G.; Friggeri, A.; Yang, Y.; Milosevic, J.; Ding, Q.; Thannickal, V.J.; Kaminski, N.; Abraham, E. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. *J. Exp. Med.* **2010**, *207*, 1589–1597, doi:10.1084/jem.20100035.

66. Seo, J.; Nam, Y.W.; Kim, S.; Oh, D.B.; Song, J. Necroptosis molecular mechanisms: Recent findings regarding novel necroptosis regulators. *Exp. Mol. Med.* **2021**, *53*, 1007–1017, doi:10.1038/s12276-021-00634-7.
67. Cai, Z.; Jitkaew, S.; Zhao, J.; Chiang, H.C.; Choksi, S.; Liu, J.; Ward, Y.; Wu, L.G.; Liu, Z.G. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. *Nat. Cell Biol.* **2014**, *16*, 55–65, doi:10.1038/ncb2883.
68. Priante, G.; Giancesello, L.; Ceol, M.; Del Prete, D.; Anglani, F. Cell death in the kidney. *Int. J. Mol. Sci.* **2019**, *20*, 1–21, doi:10.3390/ijms20143598.
69. Linkermann, A.; Bräsen, J.H.; Darding, M.; Jin, M.K.; Sanz, A.B.; Heller, J.O.; De Zen, F.; Weinlich, R.; Ortiz, A.; Walczak, H.; et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 12024–12029, doi:10.1073/pnas.1305538110.
70. Li, Z.; Rana, T.M. Therapeutic targeting of microRNAs: current status and future challenges. *Nat. Rev. Drug Discov.* **2014**, *13*, 622–638.
71. Beg, M.S.; Brenner, A.J.; Sachdev, J.; Borad, M.; Kang, Y.K.; Stoudemire, J.; Smith, S.; Bader, A.G.; Kim, S.; Hong, D.S. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Invest. New Drugs* **2017**, *35*, 180–188, doi:10.1007/s10637-016-0407-y.
72. Tricco, A.C.; Lillie, E.; Zarin, W.; Al, E. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann. Intern. Med.* **2018**, *169*, 467–473.